Thermo Fisher Scientific has launched the newly designed CE-IVD marked TaqPath Covid-19 RNase P 2.0 assay kit.
The new kit has been redesigned for the detection of active SARS-CoV-2 by identifying the presence of any one of eight gene targets from the virus.
It helps in providing accurate results even for current and future Covid-19 viral mutations by surveying multiple genes.
The TaqPath Covid-19 RNase P 2.0 kit, which has a turnaround time of approximately three hours, uses a newly designed assay for evaluating nasopharyngeal and nasal swab samples to detect active cases of Covid-19.
Thermo Fisher Scientific genetic testing solutions senior medical director Manoj Gandhi said: “SARS-CoV-2 is continuing to mutate, and this assay is the latest in our efforts to make sure our tests are future-proofed against those variants.
“With this product, we are offering customers the next generation of our Covid-19 diagnostic test that has inbuilt checks and balances in the face of emerging variants.”
The company stated that the new Covid-19 test kit uses an RNase P control to ensure sample quality, integrity and extraction.
It also noted that the first-generation TaqPath Covid-19 CE-IVD RT PCR Kit with a CE-IVD mark has been available in the market since March 2019.
Last month, Thermo Fisher Scientific received emergency use authorization from the US Food and Drug Administration for the TaqPath Covid-19 Fast PCR Combo Kit 2.0 and TaqPath COVID-19 RNase P Combo Kit 2.0.
The kits have been designed with increased target redundancy to address current and emerging SARS-CoV-2 variants.